Trk-signaling endosomes are generated by Rac-dependent macroendocytosis
Author contributions: G.V. and P.P. contributed equally to this work; G.V., P.P., Y.S., and S.H. designed research; G.V., P.P., J.R., W.A., Y.S., and S.H. performed research; G.V., P.P., J.R., W.A., Y.S., and S.H. analyzed data; and G.V., P.P., and S.H. wrote the paper.
Abstract
Why neurotrophins and their Trk receptors promote neuronal differentiation and survival whereas receptor tyrosine kinases for other growth factors, such as EGF, do not, has been a long-standing question in neurobiology. We provide evidence that one difference lies in the selective ability of Trk to generate long-lived signaling endosomes. We show that Trk endocytosis is distinguished from the classical clathrin-based endocytosis of EGF receptor (EGFR). Although Trk and EGFR each stimulate membrane ruffling, only Trk undergoes both selective and specific macroendocytosis at ruffles, which uniquely requires the Rho-GTPase, Rac, and the trafficking protein, Pincher. This process leads to Trk-signaling endosomes, which are immature multivesicular bodies that retain Rab5. In contrast, EGFR endosomes rapidly exchange Rab5 for Rab7, thereby transiting into late-endosomes/lysosomes for degradation. Sustained endosomal signaling by Trk does not reflect intrinsic differences between Trk and EGFR, because each elicits long-term Erk-kinase activation from the cell surface. Thus, a population of stable Trk endosomes, formed by specialized macroendocytosis in neurons, provides a privileged endosome-based system for propagation of signals to the nucleus.
Neurotrophin (NT) control of neuronal survival and phenotype requires the persistent activation of signaling intermediates over hours and days, a result of which is long-term alterations in gene expression (1). The molecular basis for long-term NT signaling, as exemplified by the PC12 cell model, is by persistent signaling by NGF through TrkA-receptor tyrosine kinase effectors, including Ras, Rap, and the Erk/MAP kinases (2–4). Interestingly, and unlike the case for TrkA, the EGF receptor (EGFR) tyrosine kinase, which signals through the same Erk/MAP kinases in PC12 cells, mediates transient rather than sustained signaling. Indeed, transient signaling through Erk/MAP kinases has been invoked to explain the inability of EGFR to mediate alterations of neuronal phenotype and survival (see ref. 5). The mechanisms underlying sustained vs. transient Erk/MAP kinase signaling, however, have not been elucidated.
That sustained Erk signaling by Trk is dictated directly by the receptor is suggested by the preferential binding of signaling adaptors to TrkA, such as SNT/FRS2 and ARMS, and the stimulation of a Rap1-based signaling pathway (6). Consistent with this preference, long-term signaling by TrkA receptors has been hypothesized to be specifically mediated through endosomes associated with Rap1 (4, 7, 8). However, another characteristic of Trk endosomal signaling is long-lived endosomes, as exemplified by Trk endosomal signaling that persists from the nerve terminal to the soma (1, 9). These endosomes are apparently refractory to degradation during and after retrograde transport, and can signal through Erk kinases (10, 11). The Trk-signaling endosome responsible for retrograde signaling in neurons is formed by an unusual endocytic mechanism mediated by the membrane trafficking protein, Pincher (12, 13). Trk is specifically concentrated and endocytosed at complex plasma membrane ruffles by a process termed “macroendocytosis.” Pincher confers on Trk endosomes the ability to avoid lysosomal processing (13), although the underlying mechanism is not known.
In contrast to Trk, EGFR endosomes are short-lived and their signaling through Erk kinases is transient. These properties are consistent with EGFR's established clathrin-based endocytic pathway, wherein signaling is terminated by rapid lysosomal processing (14). Thus, the differences between EGFR and Trk raise the possibility that sustained signaling may be a function of a long endosome lifetime (15). The extent to which transient or sustained signaling is an intrinsic property of Trk receptors and/or a function of the endosomal process has yet to be determined.
An understanding of Trk endosomal processing would yield insights into the selective ability of Trk to mediate sustained retrograde signaling. However, with the exception of Dynamin (8) and Pincher, the molecular entities that mediate the formation, processing, and fate of specialized Trk signaling endosomes are relatively unexplored. Here, we define a Rac-based macroendocytic process for Trk, which results in Trk multivesicular bodies that tenaciously retain molecular characteristics of early endosomes, allowing for long-term Trk endosomal signaling.
Click here to view.Acknowledgments
We thank D. Bar-Sagi, M. Chao, P. P. Di Fiore, D. Ginty (Johns Hopkins School of Medicine, Baltimore, MD), M. Goldfarb, S. Grinstein, M. McNiven, B. van Deurs, M. A. Schwartz, R. Segal (Harvard Medical School, Boston, MA), A. Sorkin, P. Stahl, and S. Yoon (Ohio State University, Columbus, OH) for providing reagents; N. Mendell for statistical analyses; and P. Brehm and G. Mandel for helpful discussions. This work was supported by National Institutes of Health Grant NS18218.
Abbreviations
| NT | neurotrophin |
| EGFR | EGF receptor |
| PIP2, | PI(4,5)P2 |
| RacN17-T7 | T7-tagged mutant RacN17 |
| EGFR-GFP | GFP-tagged EGFR |
| CCP | clathrin-coated pit |
| CCV | clathrin-coated vescicle |
| Rab5-GFP | GFP-tagged Rab5 |
| Rab7-GFP | GFP-tagged Rab7. |
Footnotes
The authors declare no conflict of interest.
This article contains supporting information online at www.pnas.org/cgi/content/full/0702819104/DC1.
References
- 1. Halegoua S, Armstrong RC, Kremer NE. Curr Top Microbiol Immunol. 1991;165:119–170.[PubMed]
- 2. Qiu MS, Green SH. Neuron. 1991;7:937–946.[PubMed]
- 3. Thomas SM, DeMarco M, D'Arcangelo G, Halegoua S, Brugge JS. Cell. 1992;68:1031–1040.[PubMed]
- 4. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, Stork PJ. Nature. 1998;392:622–626.[PubMed]
- 5. Cowley S, Paterson H, Kemp P, Marshall CJ. Cell. 1994;77:841–852.[PubMed]
- 6. Arevalo JC, Pereira DB, Yano H, Teng KK, Chao MV. J Biol Chem. 2006;281:1001–1007.[PubMed]
- 7. Wu C, Lai CF, Mobley WC. J Neurosci. 2001;21:5406–5416.
- 8. Zhang Y, Moheban DB, Conway BR, Bhattacharyya A, Segal RA. J Neurosci. 2000;20:5671–5678.
- 9. Ye H, Kuruvilla R, Zweifel LS, Ginty DD. Neuron. 2003;39:57–68.[PubMed]
- 10. Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA. Nat Neurosci. 2001;4:981–988.[PubMed]
- 11. Delcroix JD, Valletta JS, Wu C, Hunt SJ, Kowal AS, Mobley WC. Neuron. 2003;39:69–84.[PubMed]
- 12. Shao Y, Akmentin W, Toledo-Aral JJ, Rosenbaum J, Valdez G, Cabot JB, Hilbush BS, Halegoua S. J Cell Biol. 2002;157:679–691.
- 13. Valdez G, Akmentin W, Philippidou P, Kuruvilla R, Ginty DD, Halegoua S. J Neurosci. 2005;25:5236–5247.
- 14. Sorkin A. Curr Opin Cell Biol. 2004;16:392–399.[PubMed]
- 15. Yamada M, Ikeuchi T, Hatanaka H. Prog Neurobiol. 1997;51:19–37.[PubMed]
- 16. Lanzetti L, Palamidessi A, Areces L, Scita G, Di Fiore PP. Nature. 2004;429:309–314.[PubMed]
- 17. Bar-Sagi D, Feramisco JR. Cell. 1985;42:841–848.[PubMed]
- 18. Tall EG, Spector I, Pentyala SN, Bitter I, Rebecchi MJ. Curr Biol. 2000;10:743–746.[PubMed]
- 19. Benmerah A, Bayrou M, Cerf-Bensussan N, Dautry-Varsat A. J Cell Sci. 1999;112(Pt 9):1303–1311.[PubMed]
- 20. Vieira AV, Lamaze C, Schmid SL. Science. 1996;274:2086–2089.[PubMed]
- 21. Ginty DD, Segal RA. Curr Opin Neurobiol. 2002;12:268–274.[PubMed]
- 22. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. Cell. 1992;70:401–410.[PubMed]
- 23. Daniels RH, Hall PS, Bokoch GM. EMBO J. 1998;17:754–764.
- 24. Schlunck G, Damke H, Kiosses WB, Rusk N, Symons MH, Waterman-Storer CM, Schmid SL, Schwartz MA. Mol Biol Cell. 2004;15:256–267.
- 25. Bucci C, Parton RG, Mather IH, Stunnenberg H, Simons K, Hoflack B, Zerial M. Cell. 1992;70:715–728.[PubMed]
- 26. Carpenter G. Annu Rev Biochem. 1987;56:881–914.[PubMed]
- 27. Howe CL, Valletta JS, Rusnak AS, Mobley WC. Neuron. 2001;32:801–814.[PubMed]
- 28. Rink J, Ghigo E, Kalaidzidis Y, Zerial M. Cell. 2005;122:735–749.[PubMed]
- 29. Qui MS, Green SH. Neuron. 1992;9:705–717.[PubMed]
- 30. Lloyd TE, Atkinson R, Wu MN, Zhou Y, Pennetta G, Bellen HJ. Cell. 2002;108:261–269.[PubMed]
- 31. Zapf-Colby A, Olefsky JM. Endocrinology. 1998;139:3232–3240.[PubMed]




